P rimary percutaneous coronary intervention (PCI), with stent implantation when feasible, is the recommended method of reperfusion in patients with ST-segment-elevation myocardial infarction (STEMI). 1,2 Although stent implantation frequently restores normal epicardial coronary flow in patients with STEMI, myocardial reperfusion is often suboptimal and results in increased infarct size and mortality. 3-5 Numerous strategies have been proposed to improve microvascular perfusion, including pharmacological agents (eg, glycoprotein IIb/IIIa inhibitors, adenosine) and mechanical approaches (eg, thrombus aspiration, distal protection devices). 6-10 Meta-analyses of underpowered randomized trials suggested that manual aspiration thrombectomy might be associated with reduced 30-day mortality, with underlying improvements in epicardial and myocardial perfusion. 11, 12 However, in the large-scale, randomized Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial, a survival benefit of routine manual aspiration thrombectomy during primary PCI was not observed. 13
Mesh-Covered Stent in STEMI
Distal embolization may occur during stent implantation even after successful thrombus aspiration. 14 Thus, to reduce the risk of distal embolization in thrombus-containing lesions, a mesh-covered stent (MGuard Coronary Stent System, InspireMD Ltd, Tel Aviv, Israel) was developed. The MGuard is a bare metal stent (BMS) covered with an ultrathin, flexible polyethylene terephthalate mesh sleeve. 10, 15, 16 The mesh is intended to reduce distal embolization by preventing extrusion of atherothrombotic material through the stent struts during its implantation. Feasibility and short-term efficacy of MGuard stent implantation during primary PCI for STEMI was confirmed in early studies. 17, 18 Recently, the multicenter, prospective, randomized MGUARD for Acute ST Elevation Reperfusion (MASTER) trial 19 reported that among patients with STEMI, the MGuard resulted in superior rates of epicardial coronary flow and complete ST-segment resolution compared with conventional metallic stents, thus meeting its primary end point. A trend toward lower 30-day cardiac mortality was noted for patients treated with the MGuard stent. However, longer term clinical and angiographic follow-up is needed to characterize late vascular responses to the MGuard stent, especially as the only prior study with late follow-up after MGuard stent implantation was nonrandomized. 20 We herein report the 1-year clinical and 13-month angiographic outcomes from the MASTER study.
Methods

Patients
MASTER was an open-label, prospective, randomized, multicenter trial of the MGuard stent versus any commercially available metallic stent (drug-eluting stent [DES] or BMS) in patients undergoing primary PCI for STEMI. 19, 21 In brief, patients with STEMI ≤12 hours in duration intended for primary PCI were eligible for enrollment. The main exclusion criteria were electrocardiographic patterns interfering with assessment of ST-segment resolution (eg, left bundle branch block or paced rhythm); prior PCI within 6 months or coronary artery bypass graft surgery at any time; or bleeding diathesis or indication for long-term oral anticoagulation. Angiographic eligibility required planned PCI of a single de novo lesion ≤33 mm in length with reference vessel diameter ≥3.0 to ≤4.0 mm by visual estimation capable of being covered by a single study stent. Major exclusion criteria were ≥50% left main stenosis; ostial location or involvement of bifurcation with a ≥2.0-mm side branch; and previous stent proximal to or within 10-mm distal to the target lesion. In the case of an occluded infarct vessel, angiographic eligibility was assessed only after restoration of thrombolysis in myocardial infarction (TIMI) flow grade ≥2 by a guidewire, manual aspiration, or balloon predilatation.
Protocol Procedures
The protocol was approved by the ethics committee at each participating center, and informed written consent was obtained from all clinically eligible patients. Before coronary angiography patients received a loading dose of aspirin (300-325 mg chewed or 250-500 mg intravenously) and a loading dose of P2Y 12 inhibitor (600 mg clopidogrel, 60 mg prasugrel, or 180 mg ticagrelor). Procedural anticoagulation consisted of unfractionated heparin plus intravenous glycoprotein IIb/ IIIa inhibition or bivalirudin monotherapy. Emergent coronary angiography was performed using standard technique. If all angiographic eligibility criteria were met, the patient was randomized 1:1 to either the MGuard stent or a control BMS or DES (at operator discretion). Randomization was stratified by infarct-related artery (left anterior descending versus other) and use versus nonuse of thrombus aspiration. All patients were treated with aspirin (75-162 mg/d) indefinitely and a P2Y 12 inhibitor for 1 year. Clinical follow-up was performed at 30 days (±7 days), 6 months (±15 days), and 1 year (±30 days). To assess late vascular responses, angiographic follow-up at 13 months (after assessment of the 12-month clinical end point) was planned in a subgroup of 50 patients from the MGuard group.
End Points and Definitions
The primary efficacy end point was the rate of complete ST-segment resolution, defined as ≥70% reduction in the summed 12-lead extent of ST-segment elevation from the baseline to the postprocedure ECG. 19, 21 Patients were followed up for 1 year for the occurrence of major adverse cardiovascular and cerebral events (the composite of all-cause death, reinfarction, stroke, or ischemia-driven target lesion revascularization [TLR]), major adverse cardiovascular events (MACEs; the composite of cardiac death, reinfarction, or ischemia-driven TLR), stroke, stent thrombosis (Academic Research Consortium definition), 22 and major bleeding (TIMI definition). 23 All end points were adjudicated by an independent clinical events committee blinded to treatment assignment. 19, 21 Binary angiographic restenosis was defined as >50% diameter stenosis at the follow-up angiogram and was determined in-stent and in-segment (including the stent and the 5-mm proximal and distal edge margins). Late lumen loss was calculated as the difference between the postprocedure and follow-up angiographic minimal lumen diameter.
Statistical Analysis
Results are presented as numbers of patients (percentages) or mean±SD. Differences in categorical variables were analyzed using the χ 2 test or Fisher exact test, as appropriate. Continuous variables were compared using the Wilcoxon rank-sum test. Cumulative MACE
WHAT IS KNOWN
• Suboptimal reperfusion in patients with ST-segmentelevation myocardial infarction results in increased infarct size and mortality.
• The MGuard (a bare metal stent covered with a polymer mesh) was designed to reduce distal embolization during primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction.
• In the MGUARD for Acute ST Elevation Reperfusion (MASTER) trail, implantation of the MGuard stent as compared with standard metallic stents (bare metal or drug-eluting) in patients undergoing primary percutaneous coronary intervention for ST-segmentelevation myocardial infarction resulted in improved rates of thrombolysis in myocardial infarction flow and ST-segment resolution, with a trend toward lower 30-day cardiac mortality.
WHAT THE STUDY ADDS
• Implantation of the MGuard stent as compared with standard metallic stents (bare metal or drug-eluting) in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction resulted in a trend toward lower 1-year mortality.
• The 1-year rates of ischemia-driven target lesion revascularization were higher with the MGuard stent than in the control stent group, with angiographic restenosis rates expected from a bare metal stent. rates during follow-up were calculated with the Kaplan-Meier method and compared between groups using the log-rank test. Given the modest size of the BMS control arm and the numerous different types of BMS used, a post hoc propensity score-matched analysis was performed to compare the outcomes in the MGuard group with patients treated with non-drug-eluting Express BMS (Boston Scientific, Natick, MA) in the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 24 Missing baseline values for the covariates listed in the Tables in the Data Supplement were imputed using the maximum likelihood method. Matching was performed with up to a 3:1 ratio with a caliper equal to 0.2 of the SD of the logit of the propensity score. The following covariates were used for matching: age, body mass index, male sex, hyperlipidemia, diabetes mellitus, previous angina, previous MI, symptom onset to balloon time, stent length, baseline reference vessel diameter, infarct artery, and baseline TIMI flow. All tests were 2-tailed, and a P value <0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Patients and Procedures
Between July 22, 2011, and May 29, 2012, 433 patients with STEMI were randomly assigned to the MGuard (n=217) or a control stent (n=216). The baseline clinical and angiographic characteristics were well balanced between the groups. 19 The median age was 59 years, and 24% of patients were women. In 51.3% of patients the infarct-related artery was the right coronary. Baseline TIMI grade 2 or 3 flow was present in 29.8% of patients. Predilatation before stent implantation was performed in ≈50% of patients and thrombus aspiration was done in approximately two thirds of patients in each group. In the MGuard group, 96.3% of patients received the intended stent. In the control group, 86 patients (39.8%) were treated with DES, and the remainder with only BMS.
As previously reported, 19 the primary end point of postprocedure complete ST-segment resolution was significantly improved in patients randomized to the MGuard stent compared with control patients (57.8% versus 44.7%; P=0.008). The MGuard stent compared with control stents also resulted in superior rates of TIMI grade 3 flow (91.7% versus 82.9%; P=0.006) and comparable rates of myocardial blush grade 2 or 3 (83.9% versus 84.7%; P=0.81).
Clinical Outcomes
One-year follow-up was completed in 204 patients (94.9%) in the MGuard group and in 206 patients in the control group (98.6%). During follow-up there was no difference between the groups in the frequency of aspirin use (30 days: 99.5% versus 99.1%, P=0.62; 6 months: 98.1% versus 98.6%, P=0.99; and 1 year: 99.5% versus 98.6%, P=0.62) or P2Y 12 inhibitor use (30 days: 99.1% versus 98.6%, P=0.68; 6 months: 97.2% versus 99.0%, P=0.28; and 1 year: 93.6% versus 95.7%, P=0.36).
As shown in Table 1 , lower 30-day all-cause and cardiac mortality was observed in the MGuard group as compared with that in the control stent group (both 0.0% versus 1.9%; P=0.04). A similar trend was noted at 1-year follow-up (all-cause mortality: 1.0% versus 3.3%; hazard ratio, 0.28; 95% confidence interval, 0.06-1.36; P=0.09 and cardiac mortality, 0.5% versus 2.3%; hazard ratio, 0.20; 95% confidence interval, 0.02-1.69; P=0.10). The 1-year rates of major adverse cardiovascular and cerebral event and MACE were higher in the MGuard group, driven by more frequent ischemia-driven TLR (8.6% versus 0.9%; hazard ratio, 9.24; 95% confidence interval, 2.14-39.8; P=0.0003). A trend toward greater definite stent thrombosis at 1 year was present with the MGuard stent compared with control (2.3% versus 0.5%; P=0.10), with no significant differences in definite/probable stent thrombosis or reinfarction between the 2 groups. Time-to-event curves for all-cause mortality, MACE, ischemia-driven TLR, and stent thrombosis (definite or probable) are shown in the Figure (A-D) .
When the MGuard results were compared with DES or BMS considered separately in a post hoc, nonrandomized analysis, 1-year all-cause mortality was lower with the MGuard than with DES (1.0% versus 4.7%; P=0.04), but nonsignificantly different for patients treated with MGuard and BMS (1.0% versus 2.4%; P=0.29). The rates of ischemia-driven TLR were higher for MGuard as compared with either DES (8.6% versus 0.0%; P=0.002) or BMS (8.6% versus 1.6%; P=0.002). These differences resulted in higher rates of MACE with the MGuard when compared with DES (9.1% versus 3.5%; P=0.11) and BMS (9.1% versus 3.1%; P=0.04). No differences in the rates of stent thrombosis (definite or probable) were observed between the groups.
Propensity Score Analysis
Using the propensity score method, 191 patients from the MGuard group were matched according to baseline characteristics with 443 BMS-treated patients from the HORIZONS-AMI trial. After matching, the groups were similar in terms of baseline characteristics, except for slight differences in the rates of prior angina, preprocedure TIMI flow, and stent length (see Tables in the Data Supplement). No differences in the 30-day or 1-year rates of MACE or ischemia-driven TLR and TVR were present between the groups ( Table 2 ).
Angiographic Substudy
A total of 48 consecutively enrolled patients randomized to the MGuard stent were consented to return at 13 months for follow-up angiography. One patient died before the end of follow-up. Four patients refused control coronary angiography, 2 patients exited the study before the end of follow-up, and 3 patients were not available during the visit window. Finally, follow-up coronary angiography was conducted in 38 patients (79.2%), 31 of whom received a single MGuard stent. Results of the 13-month angiographic substudy are shown in Table 3 .
Discussion
The MGuard stent was designed to decrease distal embolization during primary PCI for STEMI. As we reported previously, implantation of the MGuard stent compared with standard metallic stents (BMS or DES) in patients undergoing primary PCI for STEMI resulted in higher rates of TIMI grade 3 flow and complete ST-segment resolution after the procedure, achieving its primary end point. Importantly, all-cause and cardiac mortality at 30 days were greater in patients without complete ST-segment resolution after primary PCI, resulting in fewer deaths in patients in whom the MGuard stent was implanted compared with a control stent. 19 Between 30 days and 1 year, the survival curves stayed roughly parallel, with 2 additional deaths in the MGuard group and 3 additional deaths in the control group, and thus a trend for survival was also present at 1 year. However, as the study was not powered for mortality, these findings should be interpreted with caution. Moreover, 1-year mortality was low in both groups, below that reported in most previous randomized studies 24, 25 and registries 26, 27 of DES and BMS in patients undergoing primary PCI for STEMI. Nonetheless, effective epicardial and microcirculatory reperfusion, which was more frequently observed in patients treated with the MGuard than with a standard metallic stent, may improve long-term survival. 3, 4, 14 These observations require confirmation in larger randomized trials. Before this study, data on the long-term performance (≥1 year) of the MGuard stent were limited. In a group of 41 patients treated with the MGuard stent during PCI of aged degenerated saphenous vein grafts and native coronary artery lesions in patients with acute coronary syndromes, the MACE rate at mean follow-up of 20 months was 24.4%, with all-cause mortality of 2.4%. 28 Similarly, among 57 patients treated with the MGuard stent during primary PCI for STEMI, cardiac mortality at mean follow-up of 38.7±3.1 months was 7.0%, with a major adverse cardiovascular and cerebral event rate of 8.8%. 20 As expected, the 12-month rates of ischemic TLR and TVR in the MGuard group were higher than in the control stent group, as the control group consisted of patients treated with DES as well as with BMS. The 8.6% and 11.0% 1-year TLR and TVR rates with the MGuard in the present study are similar to those observed with this device in the firstin-human study (11.1% TVR), 15 20 likely because of inclusion of longer and more complex lesions in the present trial. The 1-year TLR rates of the BMS-treated patients in the present trial were also surprisingly low, perhaps because of chance. 24 Propensity score-matched analysis of patients treated with the MGuard stent from the MASTER trial and the Express BMS from the HORIZONS-AMI trial demonstrated similar rates of ischemic TLR, TVR, and MACE between the groups, suggesting similar performance to other BMS. The 0.99mm in-stent late loss with the MGuard in the present study supports this contention. However, few MGuard patients underwent angiographic follow-up in the present protocol, and greater experience with the MGuard is required to examine low-frequency safety events, such as stent thrombosis. Compared with the first-generation stainless steel MGuard stent (which was used in most patients in this trial), the MGuard Prime stent with thinner cobalt chromium struts (80 μm as compared with 100 μm for the MGuard) may improve not only device deliverability and acute performance but might also reduce the rate of restenosis. The MGuard Prime was available and used in only 26 patients enrolled in the MASTER study. 19 Two large, multicenter randomized trials assessing the MGuard during primary PCI for STEMI are ongoing. In the MGuard Prime Stent System Clinical Trial in Patients With 29 Results of these studies should afford a balanced assessment of the competing benefits (potentially improved myocardial reperfusion, reduced infarct size, and greater survival) and risks (potentially greater restenosis) of the MGuard in comparison with conventional metallic stents.
Limitations
The MASTER trial was powered for ST-segment resolution, and not for clinical events. Thus, end points other than STsegment resolution should be considered exploratory and hypothesis generating. As the study was open-label, some degree of bias cannot be excluded. In addition, the control arm in the MASTER trial consisted of a mixture of patients treated with a commercially available DES and BMS, and randomization was not stratified by stent type. The results of the post hoc propensity-adjusted analysis should be considered hypothesis generating only. Angiographic follow-up was conducted in a small subgroup (38 patients) and was limited to patients from the MGuard stent group; thus, comparison of angiographic outcomes between study groups was not possible. Despite these limitations, this is the largest cohort of patients with STEMI treated with the MGuard stent during primary PCI with long-term clinical outcome data available.
Conclusions
In the MASTER trial of patients with STEMI undergoing primary PCI, patients treated with the MGuard stent had a trend toward reduced cardiac and all-cause mortality at 1 year. The 1-year rates of MACE in the MGuard group were higher than in the control stent group, driven by increased rate of ischemia-driven TLR, consistent with that expected from BMS. Data from ongoing randomized clinical trials powered for clinical end points are needed to weigh the competing risks and benefits of the MGuard as an alternative to conventional metallic stents in patients with STEMI.
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